Enable AccessibilityEnable Accessibility

Access to Medicines

Check our global AtM website for more information.

At Takeda we believe everyone should have access to healthcare, medicines, and vaccines no matter where they live, or how much they can afford.

Whilst the past decade has seen major public health gains and scientific breakthroughs, more than 2 billion people still lack access to basic healthcare. The communities most severely impacted are resource poor countries that lack strong healthcare systems.

We are committed to improving the lives of patients by providing sustainable access to healthcare, medicines, and vaccines. From prevention, to early diagnosis of disease, treatment and long-term patient care.

Patient Impact

Patient-focused access programs have been implemented in 52 countries and territories across Asia, Africa, Latin America, Middle East. They have enabled over 125,000 patients to receive treatment; supported Healthcare providers to screen 1.1m patients for NCDs including cancer; and trained over 4,000 community health workers to provide improved patient care.

AtM Initiatives are aligned to our Corporate Philosophy imperatives for patients.

Accelerate access to improve lives worldwide

We partner with diverse stakeholders to support the sustainability of health care systems.

PRIORITY 1: Provide timely, broad, and sustainable access to our innovative medicines worldwide.

PRIORITY 2: Ensure sustainable access to our innovative medicines for patients diagnosed with a serious condition in underserved communities, in particular where there are no medical alternatives.

PRIORITY 3: Improve patient outcomes and create societal value through partnerships.

Patient Assistance Program (PAP) under the ageis of Access to Medicine (AtM):

(Improving Access and treatment compliance through Patient Assistance Programs – PAP for patients suffering within the underserved community)

Objective: Expedite sustained access & funding in Public Health Systems for existing & upcoming innovative therapies in both Public & Private Market through innovative access programs. Takeda in India is driving PAP for patients suffering from

  • Ulcerative Colitis (UC), Crohn Disease (CD)
  • Genetic Diseases (Lysosomal Storage Diseases – Gaucher, Fabry, and Hunter)
  • Hemophilia A

Takeda’s affordability-based PAP in India aims to expand access and improve treatment compliance and Standards of Care as many patients suffering from these diseases are not able to afford the treatment and/or complete the therapy duration and thus they are left to suffer.

Description: Takeda’s group companies in India are driving different models for PAP in India. There is a “Means-based” PAP, where Takeda’s group company would provide part of treatment (as prescribed by the treating physician) free of charge to complete the annual course of treatment, once the pre-defined financial assessment and eligibility threshold is met. However. the patient is re-assessed each year as the financial condition of the patient may vary from the previous year and supported to ensure treatment compliance.

Under another innovative PAP model, Takeda’s group company is supporting partial treatment (as prescribed by the treating physician) to \ eligible patients for initial 6 months

Takeda is exploring expanding the means affordability (financial assessment) based PAP for newer therapies for the benefit of the patients with unmet needs.

Impact: Over 69 Private Hospitals and approx. 70 HCPs had been actively engaged to improve treatment access since FY 21-22.1 The PAP is effectively increasing the affordability of treatment to patients from underserved communities and supported treatment for a considerable number of patients so far. India being the host of the world’s 2nd highest number of UC and CD patients, PAP aims to further improve access and adherence. to treatment.

About our Partner:

Axios was formed in 1997 by an entrepreneurial group of health experts who believed that patients deserved better. They shared a unique vision of an organization that would bring the distinct needs of the private and public sectors together to transform conventional access to healthcare models. And that’s exactly what they did.

At the peak of the HIV/AIDS pandemic, Axios founders designed and launched an unprecedented antiretroviral (ARV) access program at a time when access to quality medications in developing countries was unheard-of. Soon after, they launched the world’s first access programs for cancer medications.

Their early programs gave millions of patients access to critical, life-saving medications and opened the world’s eyes to the feasibility of alternative, more effective access models. 25 years later, Axios continues to break new ground in the design and implementation of access to healthcare solutions across Africa, Asia, Latin America, Middle East and Europe.

Global Experience. Local Know How.

9.5 Million+ Patients Served

100 + Countries

25+ Years of Experience

Axios have worked with 80% of the top 20 pharmaceutical companies in the world’

Pre-approval access


  1. Axios monthly report. December 2022